How to Choose Bandages

A procurement officer's guide to navigating FDA classifications, performance standards, and formulary economics in wound care consumables.

---

What this is and who buys it

Bandages are among the highest-volume consumables in any healthcare supply chain, yet the category is far more technically differentiated than its commodity reputation suggests. At the broadest level, a "bandage" can be a primary dressing in direct contact with wound tissue, a secondary dressing providing securement or compression over a primary layer, or a combination system engineered to manage exudate, reduce infection risk, and protect healing tissue simultaneously. These functions map to at least five distinct product subcategories — adhesive bandages, elastic and conforming roll bandages, compression systems, specialty contact-layer dressings (foam, hydrocolloid, alginate, hydrogel), and antimicrobial dressings — each with its own regulatory pathway, performance standards, and clinical indication set.

The buyers in this category are hospital supply chain and materials management teams, ambulatory surgery center administrators, clinic purchasing officers, and long-term care procurement leads. Purchasing events are rarely random: they cluster around GPO contract renewals, formulary reviews triggered by infection control policy changes, and new service line launches such as a dedicated wound care clinic or a home health discharge formulary. The clinical consequence of a poor procurement decision is not abstract — specifying the wrong dressing class for a clinical protocol creates both outcomes risk (inadequate exudate management, maceration, wound deterioration) and a compliance exposure if the product's FDA clearance does not align with its intended use.

Demand-side pressures are intensifying. An aging patient population with higher rates of diabetic foot ulcers, venous leg ulcers, and pressure injuries is driving volume upward, while CMS reimbursement rules tie coverage of outpatient wound care supplies directly to HCPCS product codes — meaning a formulary choice that ignores code mapping can generate claim denials downstream.

---

Key decision factors

Product category and clinical indication match is the most foundational decision. The five major functional categories carry distinct FDA product codes under 21 CFR Parts 878 and 880, and procuring a dressing from the wrong category against an existing clinical protocol creates both patient safety and compliance risk. A conforming roll bandage and an alginate contact layer are both "bandages" in common speech, but they serve entirely different wound types and should never be treated as interchangeable in a formulary.

FDA clearance status and antimicrobial content deserves close scrutiny, particularly given recent regulatory movement. Standard non-antimicrobial dressings — nonresorbable gauze, hydrophilic, occlusive, and hydrogel types — are Class I devices (64 FR 53927). Antimicrobial dressings with lower antimicrobial-resistance concern are Class II, requiring 510(k) clearance and adherence to special controls. However, under FDA's November 30, 2023 proposed rule (88 FR 83774, Docket FDA-2023-N-3392), dressings containing "medically important" antimicrobials such as silver sulfadiazine are proposed for Class III status, which would require a full PMA. Any institution currently contracting antimicrobial SKUs should verify current clearance status before award and build a contract clause that addresses regulatory reclassification.

Absorption capacity and moisture vapor transmission rate (MVTR) are the two most clinically meaningful performance parameters for chronic wound dressings. Relevant test standards are EN ISO 9073-6 (absorption capacity) and EN ISO 9073-8 (strike-through time). Procurement teams should request manufacturer test data to these specific standards rather than accepting marketing language like "high absorbency," which has no standardized definition and can mask meaningful differences between competing products.

Adhesive peel strength and skin-trauma risk matter more than most commodity purchasing frameworks acknowledge. ASTM D903-98 governs peel adhesion testing for wound dressings, but bench-test data — typically measured on metal plate substrates — can run 20 times higher than real-world values on aged or fragile skin. Medical adhesive-related skin injury (MARSI) is a documented complication with particular prevalence in geriatric and oncology populations. Vendors should be asked specifically for peel force data on clinically representative substrates, not just standard bench conditions.

Microbial barrier performance for any dressing positioned as an infection control product should be evaluated against ASTM E3383-24, the current standard test method using an in vitro wound model with a defined inoculum of 3.0 × 10⁶ ± 2.0 × 10⁶ CFU/mL and contact times of 24 to 72 hours. Require vendors to supply E3383-24 test reports, not summary claims.

Shelf life and sterility assurance are operationally critical for inventory management. FDA special controls guidance for Class II wound dressings requires validated shelf-life data covering sterility maintenance, package integrity, and device functionality throughout the stated shelf period. A practical procurement target is a minimum 24-month shelf life for bulk stock; products with shorter validated shelf life increase waste exposure, particularly in lower-volume specialty areas.

GPO contract alignment and HCPCS coding close the reimbursement loop. CMS policy article A54563 defines coverage criteria for compression, conforming, and self-adherent bandages when used as secondary dressings over a qualifying wound. HCPCS A-codes govern outpatient and DME reimbursement — A6216 through A6266 for gauze products, A6448 through A6450 for compression bandages across light, moderate, and high-compression tiers. A formulary product that does not map cleanly to a covered HCPCS code will generate claim denials in outpatient and home health billing contexts.

Formulary consolidation versus clinical specificity represents a genuine strategic tradeoff. Consolidating to one or two vendors per category generates volume rebates through GPO and integrated health network agreements and reduces supply chain complexity. However, high-acuity wound programs treating diabetic foot ulcers, venous leg ulcers, or burn injuries often require specialty products that a single-vendor formulary cannot cover. Building a documented "clinical exception" pathway into any exclusive contract — with a defined approval process — protects clinicians without undermining formulary discipline.

---

What it costs

Bandage pricing spans roughly three orders of magnitude depending on product class, and actual contract pricing through GPOs is not publicly posted. The ranges below reflect published list prices and available market data; your negotiated tier pricing will differ based on volume and GPO affiliation.

• Entry tier ($0.05–$1.50 per unit): Commodity gauze rolls, elastic conforming bandages, and plain adhesive strips purchased in case quantities via GPO. This is high-volume, price-sensitive territory where small per-unit differences compound significantly at scale.
• Mid tier ($2–$15 per unit): Advanced contact-layer dressings including foam, hydrocolloid, alginate, and bordered island formats, as well as mid-tier compression systems. Significant SKU-level price variation exists within this band.
• Premium tier ($15+ per unit): Antimicrobial silver and PHMB dressings, multi-layer compression systems, absorbable synthetic wound dressings with Class II special controls, and emerging sensor-enabled "smart bandage" platforms. List prices for antimicrobial specialty dressings range from approximately $15 to $60 or more per unit. Verified commercial pricing for smart bandage platforms is not publicly available, as most remain in limited clinical distribution.

---

Common use cases

Wound care consumable needs vary dramatically by care setting, patient acuity, and procedure mix. The four most distinct procurement contexts are:

• Acute surgical care (hospital inpatient/OR): High-volume use of sterile gauze, island dressings, and surgical incision management products; formulary standardization and case-cart standardization are the primary procurement levers.
• Chronic wound management clinics: Specialty dressings dominate — alginate for highly exudating wounds, foam for moderate exudate, hydrocolloid for autolytic debridement; HCPCS code mapping is essential for outpatient billing.
• Ambulatory surgery centers and physician offices: Moderate volume with emphasis on adhesive strips, conforming bandages, and post-procedure compression; cost-per-case and vendor consolidation are the key drivers.
• Long-term care and home health: Compression bandaging systems for venous leg ulcer management, antimicrobial dressings for pressure injury prevention; DME reimbursement compliance and shelf-life management are critical given lower facility throughput.

---

Regulatory and compliance

Bandages sold in the United States are medical devices regulated under 21 CFR Parts 878 and 880, with classification ranging from Class I (general controls only, most non-antimicrobial dressings) through Class II (510(k) clearance plus special controls, antimicrobial dressings with lower AMR risk) to the proposed Class III for dressings containing medically important antimicrobials as described in FDA's November 2023 proposed rule. Procurement teams should confirm 510(k) clearance numbers for every Class II SKU on a formulary by searching the FDA 510(k) database directly; a vendor assertion of clearance is not a substitute for verification.

HIPAA relevance is limited in this category since bandages are non-data-generating consumables, but infection control compliance is not. Products positioned as microbial barriers should carry documentation to ASTM E3383-24. For compression bandage systems used in outpatient or DME contexts, CMS policy article A54563 and the relevant HCPCS A-code mapping must be confirmed before contracting to avoid downstream billing compliance issues.

---

Service, training, and total cost of ownership

Bandages are consumables rather than capital equipment, so the total cost of ownership calculation is different from a device purchase. The primary TCO drivers are unit cost at contracted volume, waste from expired or over-stocked product (particularly a risk with specialty dressings carrying shorter shelf lives), clinician compliance with formulary selections, and billing yield in outpatient settings.

Training requirements are modest for standard products but meaningful for specialty dressing systems. Multi-layer compression systems, for instance, require clinician competency in tension application to avoid under- or over-compression, and some manufacturers provide application training as part of their clinical support model — ask what is included versus separately contracted. For wound care formularies in high-acuity settings, periodic clinical review (typically annually) with a wound care specialist or clinical nurse specialist helps align formulary composition with evolving evidence and patient population changes.

Inventory management discipline — par levels, rotation protocols, and clear stock-out escalation paths — has a larger financial impact in this category than in most others because of the high-volume, low-unit-cost structure. Even a 5% waste rate on a mid-tier dressing formulary compounds to meaningful dollars at institutional scale.

---

Red flags to watch for

A vendor who cannot supply EN ISO 9073-6 and EN ISO 9073-8 test data for absorbent specialty dressings, or ASTM E3383-24 reports for products positioned as microbial barriers, should be treated with caution — the absence of this documentation suggests the product's performance claims rest on marketing rather than standardized testing.

Be wary of antimicrobial dressings whose 510(k) clearance documentation is outdated or whose clearance predates FDA's 2023 proposed reclassification activity; the regulatory ground beneath this subcategory is shifting, and a contract that locks in an antimicrobial SKU for 24–36 months without a reclassification exit clause carries real compliance exposure.

Unusually short shelf-life statements — under 18 months for a sterile product you intend to stock in volume — deserve scrutiny. Either the validated shelf life is genuinely short (raising waste-cost concerns) or the vendor has limited sterility validation data, which is a quality signal.

Finally, a product priced significantly below comparable GPO-tier offerings without a clear explanation warrants verification of manufacturing site registration and sterility validation. Counterfeit and substandard wound care products have appeared in international supply chains; for U.S. purchases, confirm FDA establishment registration of the manufacturing facility.

---

Questions to ask vendors

1. What are the specific 510(k) clearance numbers for each antimicrobial SKU in this offering, and how will you notify us if FDA finalizes the proposed Class III reclassification under Docket FDA-2023-N-3392?
2. Can you provide EN ISO 9073-6 absorption capacity and EN ISO 9073-8 strike-through time test data for each absorbent specialty dressing, and ASTM E3383-24 microbial barrier test reports for infection-barrier products?
3. What are the validated shelf lives for each SKU, and what is your return or credit policy for products approaching expiration?
4. Which HCPCS A-codes do you confirm coverage mapping for, and do you provide documentation to support outpatient billing compliance?
5. What clinician training or application support is included in the contract, and what is separately billable?
6. What is your GPO tier pricing structure, and at what volume thresholds do rebates apply?

---

Alternatives

The most consequential "make-or-buy" alternative decision in this category is new versus refurbished — but since bandages are single-use or limited-use consumables, refurbishment is not applicable. The meaningful alternatives instead involve procurement structure: GPO contract versus direct negotiation, formulary consolidation versus open formulary, and committed volume agreements versus spot purchasing.

• GPO versus direct: GPO pricing offers administrative simplicity and pre-negotiated compliance baselines; direct contracting may yield better pricing for high-volume institutions with strong purchasing leverage but requires more internal contract management capacity.
• Consolidated versus open formulary: Consolidation generates rebates and reduces SKU proliferation but may require a clinical exception process for specialty wound care needs; document the exception pathway before committing to an exclusive arrangement.
• Leasing or rental: Not applicable to consumables. However, some wound care clinic operators lease powered negative-pressure wound therapy systems that integrate proprietary dressing lines — evaluate those dressing costs as part of the device rental economics, not separately.

---

Sources

No source articles were available for this guide. The regulatory citations above (21 CFR Parts 878/880, 64 FR 53927, 88 FR 83774, CMS policy article A54563) and the referenced standards (EN ISO 9073-6, EN ISO 9073-8, ASTM D903-98, ASTM E3383-24) are drawn from the structured advisory and are verifiable through FDA.gov, the Federal Register, CMS.gov, ASTM International, and ISO.org respectively. Readers are encouraged to verify current regulatory status directly with those primary sources before contracting.